Innate Pharma (Euronext Paris: IPH - FR0010331421) is a European biopharmaceutical company developing first-in-class drugs targeting the innate immune system.
This innovative approach - currently in clinical development - opens the way to new therapeutic solutions in cancer (the company’s primary focus), infectious diseases and chronic inflammatory pathologies.
The pioneering work of Innate Pharma’s scientific founders and in-house research groups has led to the development of three product platforms (gamma delta T cells, NK cells and TLRs), each of which has been directly or indirectly validated in clinical oncology settings. With its strong scientific position in innate immunity pharmacology, a robust intellectual property portfolio, and cutting-edge R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing market immunotherapeutics market.

Speaker Profile

Laure-Hélène Mercier, Director of Investor Relations

Laure-Hélène Mercier, aged 29, joined Innate Pharma in August 2007 as Director of Investor Relations.  Prior to Innate Pharma, Laure-Hélène was a financial analyst first at Natexis Bleichroeder and then at Oddo Securities, covering the European pharmaceutical sector (2004-2007). Laure-Hélène Mercier holds a double background in science (MSc in Neurosciences) and finance (MBA-ESSEC).